Humans wait at the end of the virus growth chain
Flu has been with humans for thousands of years, but the rise of arboviruses sparks an era of desperate disease, a battle we are losing. These arboviruses—named after the arthropod mosquitoes, fleas and ticks bearing them—have skipped the virus trademark of preserving a human host. The arboviruses prefer reservoir hosts, birds which don’t catch the virus and only carry it. They enter the bird, whose blood kicks up the virulence a notch. The bird then offers up a more deadly virus to the bug’s next vector, the mosquito. Once a human is infected, the virulence is turned up beyond our natural immunity. This is one spark that heats up the world of 2018, when the trouble begins in Viral Times.
Israeli pharma promises immunity boost drug
Cancers are caused by viruses. (So many diseases start with a virus.) A new drug might be able to treat people who already have a cancer, by employing the body’s natural immunity T-cells to attack cancer cells. No mention in this link about availability of the drug, but since it’s developed outside the US, approval can be much swifter. You’d still need traditional chemo/surgery for advanced cancers. But this is a novel way to get a pharma solution to ally with natural immunity. If you can afford the booster shots.
This is the kind of medicine that the PharmAlliance wants to create in Viral Times. There is the US government in the way of approving that drug, in my future of 2021. But for now, here’s the early report on ImMucin.
A traditional vaccine helps the body’s immune system fend off foreign invaders such as bacteria or viruses, and is administered to people who have not yet had the ailment. Therapeutic vaccines, like the one Vaxil has developed, are given to sick people, and work more like a drug.
Vaxil’s lead product, ImMucin, activates the immune system by “training” T-cells –– the immune cells that protect the body by searching out and destroying cells that display a specific molecule (or marker) called MUC1. MUC1 is typically found only on cancer cells and not on healthy cells. The T-cells don’t attack any cells without MUC1, meaning there are no side effects unlike traditional cancer treatments. More than 90% of different cancers have MUC1 on their cells, which indicates the potential for this vaccine.
ImMucin is foreseen as a long-term strategy — a shot every few months, with no side effects — to stop the cancer from reoccurring after initial treatments, by ensuring that the patient’s own immune system keeps it under control.
A drug can kill viruses, in 10 years
Todd Rider, a scientist at defense-funded Lincoln Laboratories, has moved on from detecting viruses to destroying them. It will be 10 years, by some estimates, before a human version is ready to sell. But a viral pandemic might accelerate that process. Right now he’s testing it on mice. From BusinessWeek:
He describes in the recent journal article a new drug, still under development, which he has successfully used to destroy 15 viral strains, including dengue fever, a stomach virus, and a polio virus. To create it, Rider combined two proteins commonly found in the human body. One binds to viral double-stranded ribonucleic acid, a type of molecule found in all viruses. The other induces apoptosis, which is essentially programmed cell suicide. The drug acts like a homing missile that seeks out and kills cells infected by a virus. It appears to have few negative consequences and works against all diseases, even as they mutate. “Most viruses kill the host cells anyway. They are like aliens in a movie,” says Rider.
Enough of the vaccine, already
Ah, the heady drama of last fall. H1N1 was a steady source of worry, creating the Worried Well and sparking a fevered drive to stock up on vaccine. In October CBS interviewed Dr. Troyen Brennan, the Chief Medical Officer of CVS, the drug store chain.
Asked if there will be enough H1N1 vaccine to go around, Brennan said, “We do believe there will be enough. The government’s been very careful in terms of the amount of H1N1 it’s ordered and that’s coming online right now.”
And so millions of Americans queued up for a Swine Flu shot, some at CVS, along with a seasonal flu shot. Boy, was there ever enough of the H1N1 vaccine. Too much for Europe, where some claim that Swine Flu was a fake epidemic. From NPR, “Governments all across Europe are canceling orders of swine flu vaccine as frantically as they were clamoring for it a few month ago.” Alas, we’re more determined to be protected in the US.
The government is thinking about how much more swine flu vaccine to order up and pay for. But Health and Human Services spokesman Bill Hall says any decision to scale back vaccine orders is “weeks away.” Let’s take stock. Last spring the US government signed contracts for $1.5 billion worth of vaccine against the novel H1N1 virus–251 million doses. So far, 55 percent of that amount has been shipped, and something like 60 million Americans have been vaccinated. That leaves 45 percent of the contracted-for vaccine yet to be delivered. That’s 115 million doses, worth about $675 million.
Okay, it’s under a billion dollars, so it won’t even show up in the US budget.
But the cost of stress-induced concern about health, missed work time to vaccinate, isolation of the populace that didn’t want to risk being in this epidemic: much greater. There’s a payoff for coverage as breathless and shallow as the CBS Early Show stuff, thank goodness. We’re being innoculated from the sudden panic of virus outbreaks. Read the rest of this entry »
H1N1 drives deep into the lungs to kill
Even while a vaccine for H1N1 becomes far more available, doctors are discovering the virus creates infections far deeper in the lungs than seasonal flus.
The pattern of infection among the tiny percentage of people who have died from the virus mirrors the infection methods in the Spanish Flu pandemic of 1918, according to a report on CNN. The story also describes how someone dies from H1N1 infection. Their lungs cease to function well enough to give the victim sufficient air.
“Generally, flu stays in the upper airways,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. “What this shows is clearly this virus has capability of infecting and causing inflammation and destruction of cells from the trachea, all the way down into smaller cells of the lungs. “The cells of the lung get directly attacked by the virus,” said Fauci.”
Nine out of every 10 people who have died from H1N1 have “underlying conditions” that are pushed into critical status by losing respiratory function. Like a profiler on a CSI episode, the medical community is trying to match conditions to deaths. 72 percent of those who have died had obesity in their profile.
Vanderbilt University researcher Dr. William Schaffner, professor in the Division of Infectious Diseases at the university’s School of Medicine, was surprised by the H1N1 fatality-obesity connection.
“That was a striking finding,” said Schaffner. “It contributes in a very material way to what we know about risks for a severe outcome with H1N1 infection. We are keeping an eye on obesity as a risk factor for H1N1 death.”






